Epiplakin expression dynamics during colon carcinogenesis: Correlation with proliferation

Q: What samples were analyzed to study epiplakin expression during colon carcinogenesis?

The study analyzed 60 tissue samples including colon adenocarcinomas, tubular adenomas, tubulovillous adenomas, and adjacent normal colon tissues, with classification reevaluated by histology.

Q: How were epiplakin and proliferation measured in the tissues?

Immunohistochemistry assessed epiplakin and Ki67, and epiplakin optical density (OD) plus the Ki67 proliferation index were calculated using ImageJ.

Q: What relationship did the study find between epiplakin expression and Ki67?

A positive correlation was found between epiplakin expression and the Ki67 proliferation index (r = 0.317, P < 0.05).

Q: What conclusion about epiplakin is supported by the results?

Epiplakin expression decreased with colon malignancy progression, suggesting epiplakin may serve as a potential marker in colorectal cancer.

Sep 22, 2026

Upload by Genevieve

Research analyzes epiplakin expression dynamics during colon carcinogenesis and tests its relationship with tumor cell proliferation. Sixty tissue samples covering colon adenocarcinomas, tubular adenomas, tubulovillous adenomas, and adjacent normal colon tissues were reclassified histologically. Immunohistochemistry quantified epiplakin and Ki67, with ImageJ-based OD and proliferation index calculations. Epiplakin levels decreased significantly in adenocarcinoma and tubulovillous adenoma groups versus normal and tubular adenoma tissues. Adenoma groups showed higher proliferation, and epiplakin correlated positively with Ki67 (r=0.317, P<0.05), supporting epiplakin as a potential progression marker.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages9

Reading Time23 min

AccessFree to download

Introduction

Clinical background and epidemiology of colon cancer

Diagnostic screening and molecular context

Adenoma–carcinoma progression and risk differences

Materials and methods (implied)

Tissue samples and histological reevaluation

Immunohistochemistry and quantification

Statistical correlation analysis

Results (implied)

Epiplakin expression differences across groups

Ki67 proliferation index differences

Correlation between epiplakin and Ki67

Conclusion (implied)

Epiplakin as a potential marker in colorectal cancer

RESEARCH ARTICLE Epiplakin expression dynamics during colon carcinogenesis: Correlation with proliferation Damla Gül Fındık 1 ∗ , Erhan ahin 1, Özlem Türelik 2, and Gürkan Güneri 3 Colorectal cancer poses a significant global health challenge, with a considerable proportion arising from colon adenomas. Understanding the molecules involved in the carcinogenesis process is crucial for improving colon cancer diagnosis and prognosis. While research on the role of epiplakin in cancer remains limited compared to other plakin group proteins, comprehending its expression patterns and correlations can offer valuable insights into colon carcinogenesis. In this study, we analyzed 60 tissue samples, including colon adenocarcinomas, tubular adenomas (low malignancy risk group), tubulovillous adenomas (high malignancy risk group), and adjacent normal colon tissues. Classification and grading were reevaluated by histological examination. Immunohistochemistry (IHC) was performed to assess epiplakin and Ki67 expression. Epiplakin optical density (OD) and the Ki67 proliferation index were calculated using ImageJ. Statistical analyses were conducted to evaluate correlations and significance. Epiplakin expression was significantly decreased in colon adenocarcinomas [OD median 4.04 (95% CI, 3.98–4.24)] and tubulovillous adenomas [4.32 (95% CI, 4.08–4.32)] compared to normal colon tissues [4.61 (95% CI, 4.50–4.67)] and tubular adenomas [4.87 (95% CI, 4.67–4.88)](P < 0.05). Moreover, adenoma groups exhibited higher proliferation indices (P < 0.05), and a positive correlation was found between epiplakin expression and the Ki67 proliferation index (r = 0.317, P < 0.05) . Our study highlights the potential significance of epiplakin in colorectal cancer. Decreased epiplakin expression is associated with colon malignancy progression, suggesting its role as a potential marker. Keywords: Colonic neoplasms, colonic polyps, neoplasms, plakins. Introduction Colon cancer stands as a prominent public health concern on a global scale. When examining the landscape of cancer statistics worldwide, colon cancer emerges as the third most commonly diagnosed cancer and the second leading cause of cancer-related mortality [1] . From an epidemiological perspective, it is important to note that recently, a new subset of cancers of unknown primary site (CUP) with a colon-cancer proﬁle (CUP-CCP) has emerged. CUP-CCP is characterized by adenocarcinoma with features suggestive of colorectal origin, primary intra-abdominal metastases, and speciﬁc immunohistochemical staining [cytokeratin (CK) 20+, CDX2+, CK7−] . This subset, treated as colon cancer, contributes to the increased incidence of colon cancer. CK20 and CDX2 are highly speciﬁc markers for colorectal carcinomas, with CK20 expressed in 70%–100% of cases and CDX2 in 97% [2] . In early-stage colon cancer, surgical intervention alone can be curative. For stage I colon cancer, the standard treatment involves surgery without additional therapies, achieving a 5-year survival rate of 95% . At this stage, adjuvant chemotherapy is generally not recommended. For stage II colon cancer, the 5-year survival rate with surgery alone ranges from 82% to 88%[3] . Therefore, early diagnosis of colon cancer is crucial for its manageability [4] . At this point, it is important to highlight that immune cell PD-L1 expression is signiﬁcantly higher in mismatch repair (MMR)-deﬁcient (MSI-H) colon cancer compared to MMR-proﬁcient (MSI-L) tumors, with no diﬀerences observed among diﬀerent MSI-H molecular subtypes. Recommended screening for defective DNA MMR includes immunohistochemistry (IHC) and/or microsatellite instability (MSI) testing. However, challenges remain in translating the biological and technical heterogeneity of MSI testing into useful clinical information. Literature reports suggest that IHC testing of the MMR mechanism may yield diﬀerent results for a given germline mutation, potentially due to somatic mutation

FAQs

What samples were analyzed to study epiplakin expression during colon carcinogenesis?

The study analyzed 60 tissue samples including colon adenocarcinomas, tubular adenomas, tubulovillous adenomas, and adjacent normal colon tissues, with classification reevaluated by histology.

How were epiplakin and proliferation measured in the tissues?

Immunohistochemistry assessed epiplakin and Ki67, and epiplakin optical density (OD) plus the Ki67 proliferation index were calculated using ImageJ.

What relationship did the study find between epiplakin expression and Ki67?

A positive correlation was found between epiplakin expression and the Ki67 proliferation index (r = 0.317, P < 0.05).

What conclusion about epiplakin is supported by the results?

Epiplakin expression decreased with colon malignancy progression, suggesting epiplakin may serve as a potential marker in colorectal cancer.

Sep 22, 2026

Upload by Genevieve